高级别胶质瘤肿瘤样本中间充质干细胞百分比与患者生存相关
研究分析新诊断高级别胶质瘤患者中胶质瘤相关人间充质干细胞(GA-hMSC)标志物CD105+/CD73+/CD90+三阳性细胞百分比与总生存(OS)的关联。在新鲜手术标本(队列1,N=9)、第3代培养肿瘤标本(队列2,N=28)和癌症基因组图谱(TCGA)数据库中,患者OS均与肿瘤中GA-hMSC百分比相关,三阳性细胞百分比高者OS更短。结论认为GA-MSC百分比与OS呈负相关,提示GA-MSC可能促进胶质瘤侵袭行为。
要点
- 队列1中三阳性细胞低百分比组中位OS为46个月,高百分比组为12个月(HR=0.24,95%CI 0.02-0.5,P=.02)。
- 队列2中GA-hMSC低百分比组中位OS为66个月,高百分比组为11个月(HR=0.38,95%CI 0.13-0.9,P=.04)。
- TCGA数据库中CD105/CD73/CD90高共表达组中位OS为8.4个月,低共表达组为13.1个月(HR=0.4,95%CI 0.1-0.88,P=.04)。
核心结论
- GA-MSC百分比与OS呈负相关,提示GA-MSC可能在促进胶质瘤侵袭行为中发挥作用。
研究设计与样本
- 研究分析新诊断高级别胶质瘤患者中GA-hMSC标志物CD105+/CD73+/CD90+三阳性细胞百分比与OS的关联。
- 共分析3个独立队列:新鲜手术胶质母细胞瘤标本(队列1,N=9)、第3代培养肿瘤标本(队列2,N=28)和癌症基因组图谱(TCGA)数据库。
主要发现
- 队列1中三阳性细胞低百分比组中位OS为46个月,高百分比组为12个月(HR=0.24,95%CI 0.02-0.5,P=.02)。
- 队列2中GA-hMSC低百分比组中位OS为66个月,高百分比组为11个月(HR=0.38,95%CI 0.13-0.9,P=.04)。
- TCGA数据库中CD105/CD73/CD90高共表达组中位OS为8.4个月,低共表达组为13.1个月(HR=0.4,95%CI 0.1-0.88,P=.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Human mesenchymal stem cells (hMSCs) have been shown to reside as stromal cells in human gliomas as glioma-associated hMSCs (GA-hMSCs), but their biological role remains unclear. Because recent evidence indicates that GA-hMSCs drive tumor cell proliferation and stemness, we hypothesized that a higher percentage of GA-hMSCs in tumors predicts poor patient prognosis. METHOD: We determined the percentage of cells coexpressing GA-hMSC markers CD105+/CD73+/CD90+ from patients with newly diagnosed high-grade glioma and analyzed the association between this percentage and overall survival (OS) in 3 independent cohorts: fresh surgical glioblastoma specimens (cohort 1, N = 9), cultured tumor specimens at passage 3 (cohort 2, N = 28), and The Cancer Genome Atlas (TCGA) database. RESULTS: In all cohorts, patient OS correlated with the percentages of GA-hMSCs in tumors. For cohort 1, the median OS of patients with tumors with a low percentage of triple-positive cells was 46 months, and for tumors with a high percentage of triple-positive cells, it was 12 months (hazard ratio [HR] = 0.24; 95% CI: 0.02-0.5, P = .02). For cohort 2, the median OS of patients with tumors with a low percentage of GA-hMSCs was 66 months, and for tumors with a high percentage, it was 11 months (HR = 0.38; 95% CI: 0.13-0.9, P = .04). In the database of TCGA, the median OS times in patients with high and low coexpression levels of CD105/CD73/CD90 were 8.4 months and 13.1 months (HR = 0.4; 95% CI: 0.1-0.88; P = .04), respectively. CONCLUSIONS: The percentage of GA-MSCs inversely correlates with OS, suggesting a role for GA-MSCs in promoting aggressive behavior of gliomas.
引用
- Shahar T, Rozovski U, Hess KR, et al. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro Oncol. 2017. PMID: 28453745. doi:10.1093/neuonc/now239
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。